Premium
P4‐306: Age and APOE‐ɛ4 Effects on rates of clinical and structural decline in ADNI participants
Author(s) -
Holland Dominic,
McEvoy Linda,
Desikan Rahul,
Dale Anders
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.08.087
Subject(s) - cognitive decline , atrophy , alzheimer's disease neuroimaging initiative , medicine , cohort , apolipoprotein e , disease , population , demography , gerontology , dementia , psychology , environmental health , sociology
neity, as compared with original scales, and is responsive to treatment effect in MCI, enriched MCI and mild AD populations. The composite score allows for substantial sample sizes reductions in non-enriched and enriched MCI populations for a 12-month study (see Figure). Conclusions: A new composite clinical score that utilizes relevant items from validated and well-established clinical tools provides a tool that can be used as a single clinical outcome in studies that target MCI, enrichedMCI andmild AD populations. This tool will enable the use of substantially smaller sample sizes due to improved sensitivity to disease progression and treatment effects.